HTG Announces Availability Of New 384/9 Gene Expression Assay

Main Category: Genetics
Also Included In: Pharma Industry / Biotech Industry
Article Date: 15 Apr 2009 - 6:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™) today announced the launch of the quantitative nuclease protection assay (qNPA™) 384/9 gene expression assay. This new format enables the measurement of nine genes in a 384 well ArrayPlate and provides a higher plex, high throughput screening and profiling method for accelerating drug discovery and development with molecular biomarkers.

This automated assay is based on HTG's proven qNPA ArrayPlate technology platform, which allows researchers to investigate a larger, customized set of genes with greater precision than traditional high throughput screening assays. The technology allows pharmaceutical researchers who handle primary and secondary screening to quickly and efficiently measure gene expression levels of mRNA and miRNA in a wide variety of cell and tissue types.

"HTG's product extension enables our clientele who are conducting primary and secondary screening to handle increasingly more complex screening requirements," said TJ Johnson, president and CEO, HTG. "This is an extension of our existing ArrayPlate platform and we created this unique format to accommodate the diverse and dynamic needs of researchers who are looking at different numbers of genes and needed a higher plex format to do so."

HTG's qNPA technology is used to carry out quantitative, multiplexed gene-based drug discovery programs, including target validation; HTS lead optimization, metabolism, toxicology and clinical development. HTG's platform is highly flexible and designed automation-friendly; it allows scientists to test any sample, including fixed tissues, without RNA extraction or target amplification. The technology is ideal for detecting small, yet important changes in gene expression levels which other gene expression platforms cannot reliably detect.

About HTG

Privately-held HTG is based in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital. Additional information is available at http://www.htgenomics.com.

Source
HTG, Inc.